Cargando…

Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma

Background: Most integrated scores for predicting the prognosis of patients with hepatocellular carcinoma (HCC) comprise tumor progression factors and liver function variables. The FIB4 index is an indicator of hepatic fibrosis calculated on the basis of age, aspartate aminotransferase (AST) levels,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kariyama, Kazuya, Nouso, Kazuhiro, Toyoda, Hidenori, Tada, Toshifumi, Hiraoka, Atsushi, Tsuji, Kunihiko, Itobayashi, Ei, Ishikawa, Toru, Wakuta, Akiko, Oonishi, Ayano, Kumada, Takashi, Kudo, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406758/ https://www.ncbi.nlm.nih.gov/pubmed/30744175 http://dx.doi.org/10.3390/cancers11020203

Ejemplares similares

Role of hepatic resection in patients with intermediate‐stage hepatocellular carcinoma: A multicenter study from Japan
por: Tada, Toshifumi, et al.
Publicado: (2017)

Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality
por: Hiraoka, Atsushi, et al.
Publicado: (2023)

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2018)

The prognosis of elderly patients with hepatocellular carcinoma: A multi‐center 19‐year experience in Japan
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2019)

Combination therapy of transcatheter arterial chemoembolization with axitinib for the treatment of inoperable hepatocellular carcinoma
por: Nouso, Kazuhiro, et al.
Publicado: (2020)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
por: Nouso, Kazuhiro, et al.
Publicado: (2023)

Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study
por: Tada, Toshifumi, et al.
Publicado: (2020)

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
por: Tada, Toshifumi, et al.
Publicado: (2022)

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
por: Tada, Toshifumi, et al.
Publicado: (2021)

Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Tada, Toshifumi, et al.
Publicado: (2022)

New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study
por: Tada, Toshifumi, et al.
Publicado: (2022)

Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation
por: Hiraoka, Atsushi, et al.
Publicado: (2017)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
por: Tada, Toshifumi, et al.
Publicado: (2022)

The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
por: Tanaka, Kazunari, et al.
Publicado: (2023)

Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response
por: Toyoda, Hidenori, et al.
Publicado: (2021)

Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus
por: Tachi, Yoshihiko, et al.
Publicado: (2015)

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
por: Casadei-Gardini, Andrea, et al.
Publicado: (2022)

Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan
por: Toyoda, Hidenori, et al.
Publicado: (2011)

Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
por: Tada, Toshifumi, et al.
Publicado: (2017)

Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan
por: Toyoda, Hidenori, et al.
Publicado: (2019)

Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy
por: Toyoda, Hidenori, et al.
Publicado: (2014)

Natural history of liver‐related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model
por: Tada, Toshifumi, et al.
Publicado: (2019)

Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus
por: Kumada, Takashi, et al.
Publicado: (2021)

Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment
por: Chuma, Makoto, et al.
Publicado: (2022)

The albumin–bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC
por: Ito, Takanori, et al.
Publicado: (2020)

FIB nanostructures
por: Wang, Zhiming M
Publicado: (2013)

High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma
por: Kumada, Takashi, et al.
Publicado: (2013)

Long- and short-term outcomes of ERCP for bile duct stones in patients over 80 years old compared to younger patients: a propensity score analysis
por: Kanamori, Akira, et al.
Publicado: (2016)

Differences in the impact of prognostic factors for hepatocellular carcinoma over time
por: Toyoda, Hidenori, et al.
Publicado: (2017)

Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus
por: Kumada, Takashi, et al.
Publicado: (2021)

Comparing Xe(+)pFIB and Ga(+)FIB for TEM sample preparation of Al alloys: Minimising FIB‐induced artefacts
por: Zhong, Xiangli, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_67qm6of1fkggmno4mk5u0hfgir